| Identification | Back Directory | [Name]
2-((Z)-((E)-3-ethyl-5-(3-Methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)Methyl)-1-Methylpyridin-1-iuM 4-Methylbenzenesulfonate | [CAS]
1427450-47-2 | [Synonyms]
YM-01 Tosylate
2-((Z)-((E)-3-ethyl-5-(3-Methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)Methyl)-1-Methylpyridin-1-iuM 4-Methylbenzenesulfonate
(2Z,5E)-3-ethyl-5-(3-methyl-1,3-benzothiazol-2-ylidene)-2-[(1-methylpyridin-1-ium-2-yl)methylidene]-1,3-thiazolidin-4-one:4-methylbenzenesulfonate | [Molecular Formula]
C27H27N3O4S3 | [MDL Number]
MFCD28386395 | [MOL File]
1427450-47-2.mol | [Molecular Weight]
553.71 |
| Hazard Information | Back Directory | [Description]
YM-01 Tosylate is a potent antitumor agent, selectively targeting cancer cells and overcoming tamoxifen resistance. | [Uses]
HSP70-IN-4 (Compound YM-01) is an Hsp70 inhibitor with an IC50 of 3.2 μM. HSP70-IN-4 is not BBB permeable[1]. | [in vivo]
HSP70-IN-4 (Compound YM-01) cannot pass the blood-brain barrier[1]. | Animal Model: | CD1 mice[1] | | Dosage: | 20 mg/kg | | Administration: | Intravenous injection (Pharmacokinetic Analysis) | | Result: | Initial pharmacokinetics of HSP70-IN-4 (Compound YM-01; 20 mg/kg; i.v.)[1]
| hour | plasma (ng/mL) | brain (ng/g) | kidney (ng/g) | | 0.16 | 359 | 0 | 74378 | | 1 | 324 | 0 | 63231 |
|
| [IC 50]
HSP70: 3.2 μM (IC50) | [References]
[1] Miyata Y, et al. Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. ACS Chem Neurosci. 2013 Jun 19;4(6):930-9. DOI:10.1021/cn300210g |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|